Quality of Life
and
Pharmacoeconomics
in
Clinical Trials

Second Edition

Editor

Bert Spilker, Ph.D., M.D.
President
Orphan Medical, Inc.
Minnetonka, Minnesota

Adjunct Professor of Medicine
Adjunct Professor of Pharmacology
Clinical Professor of Pharmacy
University of North Carolina Schools of Medicine and Pharmacy
Chapel Hill, North Carolina

Clinical Professor of Pharmacy Practice
University of Minnesota School of Pharmacy
Minneapolis, Minnesota

Lippincott - Raven
Publishers
Philadelphia • New York
Contents

Contributors .......................................................................................................................... xv
Preface to the First Edition .............................................................................................. xxxi
Preface to the Second Edition ......................................................................................... xxxiii
Acknowledgments for the First Edition ................................................................. xxxv
Acknowledgments for the Second Edition ................................................................. xxxvii
About the Editor .............................................................................................................. xxxix
Other Books by Bert Spilker ......................................................................................... xli
Selected List of Abbreviations Used in the Text ....................................................... xliii

I: Introduction to the Field of Quality of Life Trials

1. Introduction ....................................................................................................................... 1
   Bert Spilker

2. Quality of Life Studies: Definitions and Conceptual Issues ..................................... 11
   Harvey Schipper, Jennifer J. Clinch, and Charles L. M. Olweny

3. Taxonomy of Quality of Life ...................................................................................... 25
   Bert Spilker and Dennis A. Revicki

4. The Hierarchy of Patient Outcomes ............................................................................ 33
   James F. Fries and Gurkirpal Singh

5. Measurements in Clinical Trials: Choosing the Right Approach ....................... 41
   Gordon H. Guyatt, Roman Jaeschke, David H. Feeny, and Donald L. Patrick

6. How to Develop and Validate a New Health-Related Quality of Life Instrument .... 49
   Elizabeth F. Juniper, Gordon H. Guyatt, and Roman Jaeschke

7. Adopting Higher Standards for Quality of Life Trials ........................................... 57
   Bert Spilker

8. On Learning and Understanding Quality of Life ..................................................... 59
   Susan C. Hedrick, Richard C. Taeuber, and Jennifer Erickson

9. Normalcy, Supernormalcy, and Subnormalcy ............................................................. 65
   Bert Spilker

10. Future Directions of Quality of Life Research ....................................................... 73
    Paul D. Cleary
II: Standard Scales, Tests, and Approaches to Quality of Life Assessments

11. Economic Scales and Tests ........................................... 79
   Henry G. Grabowski and Ronald W. Hansen

12. Integrating Economic Evaluations and Quality of Life Assessments ............... 85
   David H. Feeny, George W. Torrance, and Roberta Labelle

13. Social Interaction Tests and Scales .................................. 97
   Edward Guadagnoli, Paul Nordberg, and Vincent Mor

14. Cognitive Aspects of Quality of Life Assessment .................................. 107
   Ivan Barofsky

15. Psychological Aspects of Health-Related Quality of Life Measurement: Tests and Scales ........................................... 117
   Michelle J. Naughton, Sally A. Shumaker, Roger T. Anderson, and Susan M. Czajkowski

16. Functional Disability Scales ............................................ 133
   William D. Spector

17. Instruments to Measure Spiritual Status ..................................... 145
   Jan M. Ellerhorst-Ryan

18. Pharmacoeconomics and Quality of Life Research Beyond the Randomized Clinical Trial ........................................... 155
   Ron D. Hays, Cathy D. Sherbourne, and Samuel A. Bozette

III: Specific Scales, Tests, and Measures

19. Dartmouth COOP Functional Health Assessment Charts: Brief Measures for Clinical Practice ........................................... 161
   Eugene C. Nelson, John H. Wasson, Deborah J. Johnson, and Ron D. Hays

20. Derogatis Affects Balance Scale: DABS .................................. 169
   Leonard R. Derogatis and Peter J. Rutigliano

21. The European Organization for Research and Treatment of Cancer (EORTC) Modular Approach to Quality of Life Assessment in Oncology: An Update .... 179
   Neil K. Aaronson, Ann M. Cull, Stein Kaasa, and Mirjam A. G. Spranger

22. The EuroQol Instrument: An Index of Health-Related Quality of Life ............ 191
   Paul Kind

23. The Functional Assessment of Cancer Therapy (FACT) and Functional Assessment of HIV Infection (FAHI) Quality of Life Measurement System ........................................... 203
   David F. Cella and Amy E. Bonomi

24. The Functional Living Index—Cancer: Ten Years Later ................................ 215
   Jennifer J. Clinch

25. The Health Assessment Questionnaire 1995—Status and Review ..................... 227
   Dena R. Ramey, James F. Fries, and Gurkirpal Singh

26. Health Utilities Index .......................................................... 239
   David H. Feeny, George W. Torrance, and William J. Furlong
27. Measuring Health State Preferences and Utilities: Rating Scale, Time Trade-Off, and Standard Gamble Techniques
   Kathryn J. Bennett and George W. Torrance
   253

28. The McMaster Health Index Questionnaire
   Larry W. Chambers
   267

29. Nottingham Health Profile
   James McEwen and Stephen P. McKenna
   281

30. Psychological Adjustment to Illness Scale: PAIS and PAIS-SR
   Leonard R. Derogatis and Megan P. Fleming
   287

31. Quality of Life—Cancer
   Geraldine V. Padilla, Marcia M. Grant, Betty R. Ferrell, and Cary A. Presant
   301

32. The General Health Policy Model: An Integrated Approach
   Robert M. Kaplan and John P. Anderson
   309

33. SCL-90-R and the BSI
   Leonard R. Derogatis and Maureen F. Derogatis
   323

34. The SF-36 Health Survey
   John E. Ware, Jr.
   337

35. The Sickness Impact Profile
   Anne M. Damiano
   347

36. The World Health Organization Quality of Life (WHOQOL) Assessment Instrument
   Silvija Szabo (on behalf of the WHOQOL Group)
   355

IV. Choosing and Administering Tests and Treatments

37. Using Quality of Life Tests for Patient Diagnosis or Screening, or to Evaluate Treatment
   Lisa V. Rubenstein
   363

38. Choosing a Health Profile (Descriptive) and/or a Patient-Preference (Utility) Measure for a Clinical Trial
   Richard A. Berzon, Josephine A. Mauskopf, and George P. Simeon
   375

39. Data Collection Methods
   Floyd J. Fowler, Jr.
   381

40. Narrative and Quality of Life
   Deborah R. Gordon and Eugenio Paci
   387

41. Group Dynamics and Focus Groups
   Richard A. Krueger
   397

42. Incorporating Trade-Offs in Quality of Life Assessment
   Andrew J. Martin, Thomas M. Lumley, and R. John Simes
   403

43. Patient-Reported Assessments Versus Performance-Based Tests
   Carolyn C. Gotay
   413

44. Alternative and Complementary Treatments
   Barrie R. Cassileth and Christopher C. Chapman
   421
**V: Analyzing, Interpreting, and Presenting Data**

45. Quality of Life: Statistical Issues and Analysis ................................................. 427  
   *Diane L. Fairclough and Richard D. Gelber*

46. The Q-TWiST Method ................................................................. 437  
   *Richard D. Gelber, Bernard F. Cole, Shari Gelber, and Aron Goldhirsch*

47. Interpreting General Health Measures ...................................................... 445  
   *John E. Ware, Jr. and Susan D. Keller*

48. Clinical Significance of Quality of Life Data ............................................. 461  
   *Eva G. Lydick and Robert S. Epstein*

49. Evaluating and Comparing Life Events Data with Quality of Life Data .......... 467  
   *Bert Spilker*

50. Presentation of Quality of Life Data ....................................................... 477  
   *John R. Schoenfelder and Bert Spilker*

**VI: Special Perspectives on Quality of Life Issues**

51. Quality of Life Assessments in Clinical Trials: An Ethical Perspective ........ 489  
   *Robert J. Levine*

52. Quality of Life Measures in Health Care and Medical Ethics ....................... 497  
   *Dan Brock*

53. Cultural Considerations .............................................................................. 511  
   *Thomas M. Johnson*

54. The Role of Quality of Life Assessments in Medical Practice ..................... 517  
   *Albert W. Wu and Kathleen A. Cagney*

55. Anthropological Perspectives: The Importance of Culture in the Assessment of  
    Quality of Life ...................................................................................... 523  
   *Peter J. Guarnaccia*

56. Quality of Life: The Nursing Perspective .................................................. 529  
   *Pamela S. Hinds and Claudette G. Varricchio*

57. An Industry Perspective ............................................................................. 535  
   *Bert Spilker and Stanley B. Garbus*

58. A Marketing Perspective: Theoretical Underpinnings ................................ 541  
   *Louis A. Morris, Thomas K. Beckett, and Karen J. Lechter*

59. A Marketing Perspective: Practical Applications ......................................... 549  
   *Thomas K. Beckett*

60. An Epidemiologic Perspective .................................................................... 555  
   *David S. Sugano and Newell E. McElwee*

61. Legal Considerations in the Development and Use of HRQL Measures for National  
    and International Clinical Trial Research ............................................... 563  
   *Richard A. Berzon and John M. Conley*

62. Regulatory Perspectives on Quality of Life Issues .................................... 569  
   *Mary S. McCabe, Dale Shoemaker, Robert J. Temple, Gregory Burke,  
     and Michael A. Friedman*
### VII: Cross-Cultural and Cross-National Issues

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>63.</td>
<td>Language and Translation Issues</td>
<td>Catherine Acquadro, Bernard Jambon, David Ellis, and Patrick Marquis</td>
<td>575</td>
</tr>
<tr>
<td>64.</td>
<td>Quality of Life in Ethnic Groups</td>
<td>Janis F. Hutchinson</td>
<td>587</td>
</tr>
<tr>
<td>65.</td>
<td>Assessing Health-Related Quality of Life in Disadvantaged and Very Ill Populations</td>
<td>Margot K. Ettl, Ron D. Hays, William E. Cunningham, Martin F. Shapiro, and C. Keith Beck</td>
<td>595</td>
</tr>
<tr>
<td>66.</td>
<td>Conceptual Issues and Considerations in Cross-Cultural Validation of Generic Health-Related Quality of Life Instruments</td>
<td>Roger T. Anderson, Mary McFarlane, Michelle J. Naughton, and Sally A. Shumaker</td>
<td>605</td>
</tr>
<tr>
<td>68.</td>
<td>Dimension-Specific Instruments That May Be Used Across Cultures</td>
<td>Michelle J. Naughton and Ingela K. Wiklund</td>
<td>633</td>
</tr>
<tr>
<td>70.</td>
<td>A Mini-Handbook for Conducting Small-Scale Clinical Trials in Developing Countries</td>
<td>Harvey Schipper, Charles L. M. Olweny, and Jennifer J. Clinch</td>
<td>669</td>
</tr>
<tr>
<td>71.</td>
<td>Evaluating Instruments Used Cross-Nationally: Methods from the IQOLA Project</td>
<td>John E. Ware, Jr., Barbara L. Gandek, Susan D. Keller, and the IQOLA Project Group</td>
<td>681</td>
</tr>
<tr>
<td>72.</td>
<td>Applying Quality of Life Principles in International Cancer Clinical Trials</td>
<td>Jürg Bernhard, Christoph D. T. Hürny, Alan Coates, and Richard D. Gelber</td>
<td>693</td>
</tr>
<tr>
<td>73.</td>
<td>Cross-Cultural Instrument Equating: Current Research and Future Directions</td>
<td>David F. Cella, Stephen R. Lloyd, and Benjamin D. Wright</td>
<td>707</td>
</tr>
</tbody>
</table>

### VIII: Health Policy Issues

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>74.</td>
<td>Applications of Health Status Assessment to Health Policy</td>
<td>Donald L. Patrick and Pennifer Erickson</td>
<td>717</td>
</tr>
<tr>
<td>75.</td>
<td>Ethical and Medical Basis of Health Care Rationing</td>
<td>Stefan Björk</td>
<td>729</td>
</tr>
<tr>
<td>76.</td>
<td>Using Decision-Analysis Approaches to Integrate QOL and Cost Data in Drug Therapy Selection</td>
<td>William F. McGhan</td>
<td>741</td>
</tr>
<tr>
<td>Chapter</td>
<td>Title</td>
<td>Authors</td>
<td>Page</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>77.</td>
<td>Outcomes Research and Quality of Care</td>
<td>Donald M. Steinwachs, Albert W. Wu, and Kathleen A. Cagney</td>
<td>747</td>
</tr>
<tr>
<td>78.</td>
<td>Health Policy Implications of Using Quality of Life Measures in the Economic Evaluation of Health Care</td>
<td>Alan H. Williams</td>
<td>753</td>
</tr>
<tr>
<td>79.</td>
<td>Rules for Evaluating Medical Technologies</td>
<td>David M. Eddy</td>
<td>761</td>
</tr>
<tr>
<td>80.</td>
<td>International Price Comparisons</td>
<td>Patricia M. Danzon</td>
<td>773</td>
</tr>
<tr>
<td>81.</td>
<td>Roles of Government Agencies in Support and Application of Quality of Life Research</td>
<td>Susan G. Nayfield</td>
<td>779</td>
</tr>
<tr>
<td>IX:</td>
<td>Special Populations to Assess Quality of Life</td>
<td></td>
<td></td>
</tr>
<tr>
<td>82.</td>
<td>Measuring Health-Related Quality of Life in Pediatric Populations: Conceptual Issues</td>
<td>Peter L. Rosenbaum and Saroj Saigal</td>
<td>785</td>
</tr>
<tr>
<td>83.</td>
<td>Measuring Health Outcomes in Pediatric Populations: Issues in Psychometrics and Application</td>
<td>Jeanne M. Landgraf and Linda N. Abetz</td>
<td>793</td>
</tr>
<tr>
<td>84.</td>
<td>Geriatrics: Perspective on Quality of Life and Care for Older People</td>
<td>T. Franklin Williams</td>
<td>803</td>
</tr>
<tr>
<td>85.</td>
<td>Frail Older Patients: Creating Standards of Care</td>
<td>Marsha D. Fretwell</td>
<td>809</td>
</tr>
<tr>
<td>86.</td>
<td>Measuring Health-Related Quality of Life in Older and Demented Populations</td>
<td>Anita L. Stewart, Cathy D. Sherbourne, and Meryl Brod</td>
<td>819</td>
</tr>
<tr>
<td>87.</td>
<td>Substance Abuse Disorders</td>
<td>David S. Metzger, Richard F. Davis, and Charles P. O'Brien</td>
<td>831</td>
</tr>
<tr>
<td>88.</td>
<td>Rehabilitation: Issues in Functional Assessment</td>
<td>Ralph R. Turner</td>
<td>839</td>
</tr>
<tr>
<td>89.</td>
<td>Defining Quality of Life in Chronic Pain</td>
<td>Victor C. Lee and John C. Rowlingson</td>
<td>853</td>
</tr>
<tr>
<td>90.</td>
<td>Quality of Life after Coronary Revascularization Procedures</td>
<td>Carol E. Cornell, James M. Raczynski, and Albert Oberman</td>
<td>865</td>
</tr>
<tr>
<td>X:</td>
<td>Specific Problems and Diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>91.</td>
<td>Cardiovascular Disorders</td>
<td>Nanette K. Wenger, Michelle J. Naughton, and Curt D. Furberg</td>
<td>883</td>
</tr>
<tr>
<td>92.</td>
<td>Hypertension</td>
<td>Ingela K. Wiklund</td>
<td>893</td>
</tr>
<tr>
<td>93.</td>
<td>Neurologic Illness</td>
<td>Robert S. Wilson, Christopher G. Goetz, and Glenn T. Siebhins</td>
<td>903</td>
</tr>
</tbody>
</table>
94. Quality of Life Assessment for People with Epilepsy .............................................. 909
   Joyce A. Cramer

95. Severe Mental Illness in the Community ............................................................. 919
   Anthony F. Lehman and Barbara J. Burns

96. Inflammatory Bowel Disease ................................................................................. 925
   Douglas A. Drossman

97. Quality of Life Assessment in Gastrointestinal Surgery ....................................... 937
   Robin S. McLeod

98. Measuring Disease-Specific Quality of Life in Men with Benign Prostatic Hyperplasia ............................................................... 945
   Harry A. Guess

99. Determining Quality of Life in the Renal Replacement Therapies ......................... 953
   Atara Kaplan De-Nour and Andrew L. Brickman

100. Quality of Life in Chronic Obstructive Pulmonary Disease ................................. 961
    A. John McSweeney and Karen T. Labuhn

101. Asthma and Allergy .............................................................................................. 977
    Elizabeth F. Juniper and Gordon H. Guyatt

102. Diabetes Mellitus .................................................................................................. 983
    Richard S. Beaser, Sharon B. Garbus, and Alan M. Jacobson

103. Cancer: Psychosocial Aspects .............................................................................. 993
    Ivan Barofsky

104. Incorporating Quality of Life Assessment into Clinical Cancer Trials .................... 1003
    Michael D. E. Goodyear and Michael A. Fraumeni

105. Quality of Life in Bone Marrow Transplant ........................................................ 1015
    Betty R. Ferrell, Marcia M. Grant, and Marie B. Whedon

106. Chronic Rheumatic Disorders .............................................................................. 1029
    Elizabeth W. Karlson, Jeffrey N. Katz, and Matthew H. Liang

107. Quality of Life in Orthopaedics .......................................................................... 1039
    James G. Wright

108. Measurement of Visual Functioning and Health-Related Quality of Life in Eye Disease and Cataract Surgery .......................................................... 1045
    Carol M. Mangione, Paul P. Lee, and Ron D. Hays

109. AIDS ...................................................................................................................... 1053
    A. David Paltiel and Aaron A. Stinnett

110. Nutrition and Quality of Life Measurement ......................................................... 1063
    Carol E. Smith and Susan V. M. Kleinbeck

XI: Pharmacoeconomics

111. Relationship of Pharmacoeconomics and Health-Related Quality of Life .............. 1077
    Dennis A. Revicki

112. Designing and Conducting Cost-Benefit Analyses .............................................. 1085
    Magnus Johannesson and Milton C. Weinstein
113. Designing and Conducting Cost-Minimization and Cost-Effectiveness Analyses ................................................................. 1093
   Brian E. Rittenhouse

114. Designing and Conducting Cost-Utility Analyses ................................................................. 1105
   George W. Torrance

115. Practical Aspects of Designing and Conducting Pharmacoeconomic Studies .................. 1113
   Andrew M. Baker

116. Developing Guidelines for Pharmacoeconomic Trials ................................................................. 1123
   Bert Spilker

117. Users of Pharmacoeconomic Data .............................................................................................. 1131
   Alan L. Hillman and Joseph A. Leveque

118. Use of Pharmacoeconomic Data by Regulatory Authorities .................................................. 1141
   Paul P. Glasziou and Andrew S. Mitchell

119. Use of Pharmacoeconomic Data by Pharmaceutical Companies ........................................... 1149
   Brian Lovatt

120. Uses of Pharmacoeconomic Data by Policy-Makers and Pharmaceutical Benefit Managers ................................................................................. 1153
   Stephen W. Schondelmeyer

121. Use and Opportunities for Administrative Databases in Pharmacoeconomic Research .............................................................................................. 1165
   John E. Paul and Hugh H. Tilson

122. Problems in Undertaking Pharmacoeconomic Assessments in Phase III Clinical Trials: The Case of Colony-Stimulating Factors ................................................................................. 1173
   Michael F. Drummond, Joseph Menzin, and Gerry Oster

123. Comparing Pharmacoeconomic Data from Different Clinical Trials ........................................ 1179
   Flemming Ørnskov and Bengt G. Jönsson

124. A Bayesian Approach to the Economic Evaluation of Health Care Technologies .......... 1189
   David A. Jones

125. Using Decision Analysis to Conduct Pharmacoeconomic Studies ........................................ 1197
   Judith T. Barr and Gerald E. Schumacher

126. Threats to the Validity of Pharmacoeconomic Analyses Based on Clinical Trial Data .............................................................................................. 1215
   Brian E. Rittenhouse and Bernie J. O'Brien

127. The Future of Pharmacoeconomics .............................................................................................. 1225
   Michael F. Drummond

Subject Index .......................................................................................................................................................... 1229

Instruments Index ................................................................................................................................................. 1255